The mark consists of the wording "MONJUVI" located to the left of three arrow points.
Mark For: MONJUVI™ trademark registration is intended to cover the categories of
>Color is not claimed as a feature of the mark. The mark consists of the wording "MONJUVI" located to the left of three arrow points.
Research |
![]() ![]() ![]() ![]() ![]() |
Serial Number | 88664626 |
Mark Literal Elements | MONJUVI |
Mark Drawing Type | 3 - AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/ LETTER(S)/NUMBER(S) |
Mark Type | TRADEMARK. SERVICE MARK |
Standard Character Claim | No |
Register | PRINCIPAL |
Current Location | TMEG LAW OFFICE 101 - EXAMINING ATTORNEY ASSIGNED 2019-12-18 |
Basis | 1(b) 44(d) |
Class Status | ACTIVE |
Primary US Classes |
|
Primary International Class |
|
Filed Use | No |
Current Use | No |
Intent To Use | Yes |
Filed ITU | Yes |
44D Filed | Yes |
44E Current | No |
66A Current | No |
Current Basis | No |
No Basis | No |
Attorney Name | Michael J. Leonard |
Attorney Docket Number | 114353.00088 |
2019-10-22 | Application Filed |
2019-10-25 | Location: NEW APPLICATION PROCESSING |
2019-10-25 | Status: Live/Pending |
2019-10-25 | Transaction Date |
2019-12-16 | Published for Opposition |
2019-12-16 | Trademark Registered |
2019-12-18 | Location: TMEG LAW OFFICE 101 - EXAMINING ATTORNEY ASSIGNED |
2019-12-18 | Status: A non-final Office action has been sent (issued) to the applicant. This is a letter from the examining attorney requiring additi |
Party: | ![]() |
Address | Semmelweisstrasse 7 Planegg GERMANY D-82152 |
Legal Entity Type | Aktiengesellschaft |
Legal Entity State | GERMANY |
![]() | IMAGE/JPEG | 2019-10-22 |
![]() | MULTI | 2019-10-22 |
![]() | APPLICATION/XML | 2019-10-30 |
![]() | MULTI | 2019-11-17 |
![]() | MULTI | 2019-11-23 |
![]() | XML | 2019-12-15 |
![]() | XML | 2019-12-18 |
![]() | XML | 2019-12-18 |
24.15.10 | Arrows, more than one; More than one arrow |
241504 | Arrowheads |
241510 | Arrows, more than one; More than one arrow |
IC 005. US 006 018 044 046 051 052. G & S: (Based on 44(d) Priority Application) (Based on Intent to Use) Pharmaceuticals and pharmaceutical preparations for human and veterinary use for the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; vaccine preparations; vaccines; biological preparations in the nature of antibodies for use in the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; antibodies sold as a component ingredient of pharmaceuticals for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines; diagnostic preparations for medical or veterinary purposes; biological preparations for human medical diagnostics and analysis for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; sanitary preparations for medical use; medical diagnostic reagents; clinical medical reagents; biological preparations for medical and veterinary purposes for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis
IC 042. US 100 101. G & S: (Based on 44(d) Priority Application) (Based on Intent to Use) Research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; scientific and technological services and research and design services, namely, scientific research, analysis, and testing services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; biological research and medical research; chemical and biochemical analysis services; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; clinical research in connection with the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development services in the field of antibodies
International Codes: | 5 |
U.S. Codes: | 006,018,044,046,051,052 |
International Codes: | 42 |
U.S. Codes: | 100,101 |
Type Code | Type |
---|---|
DM0000 | The mark consists of the wording MONJUVI located to the left of three arrow points. |
CC0000 | Color is not claimed as a feature of the mark. |
Description | Date | Proceeding Number |
---|---|---|
NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2019-12-18 | 6325 |
NON-FINAL ACTION WRITTEN | 2019-12-18 | 73363 |
NON-FINAL ACTION E-MAILED | 2019-12-18 | 6325 |
ASSIGNED TO EXAMINER | 2019-12-15 | 73363 |
APPLICANT AMENDMENT PRIOR TO EXAMINATION - ENTERED | 2019-11-22 | 70138 |
ASSIGNED TO LIE | 2019-11-21 | 70138 |
TEAS VOLUNTARY AMENDMENT RECEIVED | 2019-11-17 | |
NOTICE OF DESIGN SEARCH CODE E-MAILED | 2019-10-30 | |
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2019-10-29 | |
NEW APPLICATION ENTERED IN TRAM | 2019-10-25 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.